A5026178160- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Cancer Mechanisms and Therapy
- HIV/AIDS drug development and treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- Liver Diseases and Immunity
- Drug-Induced Hepatotoxicity and Protection
- Lung Cancer Treatments and Mutations
- Pediatric Hepatobiliary Diseases and Treatments
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Pharmacogenetics and Drug Metabolism
- Renal cell carcinoma treatment
- Gastroesophageal reflux and treatments
- Hepatitis Viruses Studies and Epidemiology
- Genetic and Kidney Cyst Diseases
- Organ Transplantation Techniques and Outcomes
- Liver physiology and pathology
- Animal Virus Infections Studies
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
2016-2025
Japanese Red Cross Hiroshima College of Nursing
2016-2022
The Japanese Society of Gastroenterological Surgery
2016
Hiroshima City Asa Citizens Hospital
2005-2015
Kyoto Prefectural University of Medicine
2005-2006
Hiroshima University
1995-2004
Tokai University
1994-1997
Yokohama City Seibu Hospital
1995
St. Marianna University School of Medicine
1995
University of Tsukuba
1994
Bepirovirsen is an antisense oligonucleotide that targets all hepatitis B virus (HBV) messenger RNAs and acts to decrease levels of viral proteins.
<b><i>Introduction:</i></b> We evaluated the efficacy and safety of lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy for patients (<i>n</i> = 88) with intermediate-stage hepatocellular carcinoma (HCC). <b><i>Methods:</i></b> Eighty-eight who obtained tumor control by LEN treatment were analyzed; 30 received followed TACE (LEN-TACE therapy), 58 monotherapy. Propensity score matching was performed,...
Background: Lenvatinib (LEN) has been approved for patients with unresectable hepatocellular carcinoma (u-HCC) since March 2018 in Japan. We performed a retrospective nationwide multicenter study to clarify the clinical characteristics of LEN real-world practice. Methods: A total 343 u-HCC who received from May 2020 at 23 sites Japan were registered. Results: During median observation period 10.5 months, 143 died. In Child-Pugh (n = 276) and B 67) patients, overall survival (OS) was 21.0 9.0...
We investigated pretreatment neutrophil-to-lymphocyte ratio (NLR) for predicting survival outcomes of atezolizumab plus bevacizumab therapy hepatocellular carcinoma (HCC) and determined the predictive ability combined liver reserve-NLR.This retrospective, multicenter study enrolled 242 patients receiving unresectable HCC. Pretreatment NLR <2.56 was designated as "low group" ≥2.56 "high (120 122 patients, respectively). Propensity score-matched analysis undertaken between low high groups.In...
Abstract Aim We aimed to evaluate the effect of pemafibrate, a selective peroxisome proliferator‐activated receptor‐α modulator, on patients with primary biliary cholangitis (PBC) complicated by dyslipidemia. Methods In total, 61 PBC (Add‐on group: 33 ursodeoxycholic acid [UDCA] + pemafibrate combination therapy; Switch 28 who switched from UDCA other fibrates therapy) were included in study. Changes aspartate aminotransferase (AST), alanine (ALT), gamma‐glutamyl transferase (GGT), alkaline...
Background and aim This study aimed to elucidate whether interferon (IFN)-free direct-acting antiviral (DAA) therapy for hepatitis C after curative treatment of hepatocellular carcinoma (HCC) promotes HCC recurrence in a real-world large-scale cohort. Methods multicenter was conducted by the Japanese Red Cross Hospital Liver Study Group. retrospective analyzed 516 patients who underwent with either IFN (n = 148) or IFN-free DAA 368) treatment; 78 IFN-treated 347 DAA-treated achieved...
In order to know the present status of drug-induced liver injury (DILI) in Japan, we data prospectively collected DILI cases between 2010 and 2018 from 27 hospitals.Drug-induced diagnosed by experts hospitals all over Japan have been since 2010. Alanine aminotransferase level ≥150 U/L and/or alkaline phosphatase ≥2× upper limit normal were inclusion criteria.In total, 307 (125 male 182 female individuals) aged 17 86 years old collected. The types as follows: 64% hepatocellular type, 20%...
Portal vein thrombosis (PVT) is one of the most critical disorders in liver disease patients. These patients have imbalance coagulation and inhibition resulting from decreased levels inhibitory factors, such as protein C, S, antithrombin III (AT-III). We designed this randomized, double-blind, placebo-controlled trial comparing safety efficacy AT-III for PVT with those who received no treatment.Eligible were diagnosed association thrombus, without tumor thrombus more than 50% cross-sectional...
In patients with HBV and HCV coinfection, reactivation leading to severe hepatitis has been reported the use of direct-acting antivirals (DAAs) treat infection. Here we studied molecular mechanisms behind this viral interaction. coinfected cell culture humanized mice, replication was suppressed by coinfection. vitro, suppression attenuated when interferon (IFN) signaling blocked. vivo, viremia, after initial superinfection, rebounded following clearance DAA treatment that accompanied a...
Objectives Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or macroscopic vascular invasion (MVI). The application of sorafenib has been approved by Japanese Government‐sponsored Medicare HCC. In this retrospective cohort study we aimed compare various aspects HAIC in Child–Pugh A patients HCC who were otherwise free extrahepatic metastasis....
<b><i>Objective:</i></b> To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT). <b><i>Methods:</i></b> This retrospective study included 108 HCC PVTT main trunk or first branch Child-Pugh ≤7. Sixty-eight received HAIC RT 40 sorafenib. Patients were then assigned to group...
Abstract Background It is unclear whether the fibrosis 4 index (FIB-4), a marker of liver fibrosis, at baseline and change in FIB-4 after sustained virological response (SVR) associated with incident hepatocellular carcinoma (HCC) risk. In this study, we examined association HCC risk high (&gt;3.25) any time point SVR. Methods A total 3823 patients who received direct-acting antiviral treatment achieved SVR were enrolled. The was measured 24 weeks end achievement (SVR24), 1, 2, 3 years...
Abstract Aim The diagnosis of drug‐induced liver injury (DILI) is challenging. We modified the revised electronic version Roussel Uclaf Causality Assessment Method (RUCAM) for DILI (RECAM), scoring system developed in US and Spanish cohorts 2022, RECAM‐J 2023 to align with clinical practice Japan. In current study, we introduce verify its performance context Japanese patients DILI. Methods After translation RECAM into Japanese, modifications were made develop without any alteration scores....
Backgrounds & Aims We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination NS3/4A asunaprevir (ASV), patients chronic hepatitis C virus genotype 1b infection. Methods This is a nationwide multicenter study conducted by Japanese Red Cross Liver Study Group. The sera were obtained from 68 virological 24 weeks DCV/ASV treatment. RASs and NS3 determined population sequencing. Results...
Abstract Background and Aim Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC) distant metastasis, unresectable HCC, HCC refractory to transcatheter arterial chemoembolization (TACE) or macroscopic vascular invasion (MVI). Also, hepatic infusion chemotherapy (HAIC) has been used in Southeast East Asian countries. However, clearer information needed choosing appropriately between these therapies. Methods The subjects were 391 HAIC 431 sorafenibs...
Although a strong antitumor effect of lenvatinib (LEN) has been noted for patients with unresectable hepatocellular carcinoma (HCC), there are still no reports on the prognosis disease progression after first-line LEN therapy.Patients (n = 141) HCC, Child-Pugh class A liver function, and an Eastern Cooperative Oncology Group performance status (ECOG-PS) 0 or 1 who were treated from March 2018 to December 2019 enrolled.One hundred five as therapy, 53 whom had progressive (PD) at radiological...
Summary Chronic HCV –infected patients tend to have vitamin D deficiency, suggesting that supplementation may enhance the efficacy of treatment with pegylated interferon ( PEG ‐ IFN ) and ribavirin RBV ). We therefore assessed effects on viral response / . Eighty‐four genotype 1b were randomized, 42 oral (1000 IU/day) nonsupplementation (control), from week 8 end therapy. The primary point was undetectable RNA at 24 (viral [ VR ]). rate significantly higher in than control group (78.6% vs...
This study aimed to describe the real-world efficacy and safety of sofosbuvir (SOF) + ribavirin (RBV) for chronic hepatitis C, genotype 2.This was a retrospective analysis nationwide, multicenter registry including 914 C 2 Japanese patients treated with SOF RBV 12 weeks. The rate sustained virologic response at weeks after treatment (SVR12), incidence adverse events, changes in serological parameters were analyzed.Treatment completed 98.9% patients. Ribavirin dose reduction required 29.7%...